Annovis Bio, Inc. (ANVS)

Market Cap	96.74M
Revenue (ttm)	n/a
Net Income (ttm)	-28.15M
Shares Out	8.16M
EPS (ttm)	-2.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,140
Open	11.69
Previous Close	11.85
Day's Range	11.4 - 12.09
52-Week Range	8.39 - 23.91
Beta	1.22
Analysts	Buy
Price Target	46.92 (+305.5%)
Earnings Date	Nov 9, 2022

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. T...

• Industry: Biotechnology
• IPO Date: Jan 29, 2020
• CEO: Maria Maccecchini
• Employees: 3
• Stock Exchange: NYSE
• Ticker Symbol: ANVS

Analyst Forecast

According to 9 analysts, the average rating for ANVS stock is "Buy." The 12-month stock price forecast is 46.92, which is an increase of 305.53% from the latest price.

Price Target

$46.92

(305.53% upside)

Analyst Consensus: Buy